'Bullish Options Flow' in Teva Pharma (TEVA) Continues -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Cantor Fitzgerald Sees ~4.9M Shares of Teva (TEVA) Being Bought Amid TASE Index Rebalance
November 30, 2017 12:22 PM ESTCantor Fitzgerald analyst Louise Chen weighed in on the TASE index weight re-balancing for Mylan (NYSE: MYL) and Teva (NASDAQ: TEVA) after Mylan announced it is voluntarily delisting its ordinary shares from trading on the Tel Aviv Stock Exchange... More
Teva Pharma (TEVA) Announces NEJM Publishes Data from Pivotal Phase III Trial of Fremanezumab for Preventive Treatment of Chronic Migraine
November 29, 2017 5:07 PM ESTTeva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the publication of data from the pivotal Phase III HALO study evaluating the efficacy, safety and tolerability of two subcutaneous dose regimens of fremanezumab for the preventive treatment of chronic migraine (CM). These data were published online today by the New England Journal of Medicine (NEJM) and will appear in a subsequent print issue.
The burden of illness faced by those with migraine is immense and can negatively impact every facet of their lives underscoring a significant unmet... More
Notable Call Buying Activity in Teva Pharma (TEVA) Continues -Susquehanna
November 29, 2017 2:45 PM ESTSusquehanna options strategist Alison Edwards notes continued buying activity Teva Pharma (NYSE: TEVA) , as an opening investor bought 15k Jan 15 Calls, most for $1.10, creating ~750k shares to buy.
... MoreTeva Pharma (TEVA) PT Raised to $16 at Mizuho Securities on Announced Major Cost Cuts
November 29, 2017 6:45 AM ESTMizuho Securities raised its price target on Teva Pharma (NYSE: TEVA) to $16.00 (from $12.00) while maintaining a Neutral rating, following a model update fueled by conversations with management.
Analyst Irina Koffler notes a positive outlook on the shares, following conversations with management... More
